A Phase 1 interventional study of PRO 140 in HIV Infections, sponsored by CytoDyn, Inc.. Completed at 1 site in United States. Open to male participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-03-14.
Sponsored by CytoDyn, Inc. · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 2,802 studies in HIV Infections with a site in United States — 83 open to participants now, 140 under way, 11 of them phase 3. HIV Infections · United States.
Among the 2,802 studies in HIV Infections with a site in United States, this one is the 1,807th largest by enrollment of the 2,150 interventional ones that give a count, is one of 107 that started in 2004, is one of 671 in phase 1, and was the 1,406th registered.
4,737 studies on the registry are indexed under HIV Infections; 247 are open to participants now.
Browse HIV Infections studies →83 of the 2,802 studies in HIV Infections with a site in United States are open now. Recruiting first, the newest first:
National Institute of Allergy and Infectious Diseases (NIAID) · Sites in United States
Ages 18+
ViiV Healthcare · Sites in United States
Ages 18–55 · Healthy volunteers
Louisiana State University Health Sciences Center in New Orleans · Sites in United States
Ages 40+
American University · Sites in United States
Ages 18+ · Men only
Gilead Sciences · Sites in United States, Australia, Japan
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 159 HIV Infections studies recruiting now, 104 (65%) set no upper age limit and 42 (26%) stop at 75 or younger; 31 take children under 18; 60 take healthy volunteers.
This study: 18 Years to 50 Years · male · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
2,802 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 749 · Phase 2 588 · Phase 3 337 · Phase 4 157
First in 1984; this study’s year is marked. 107 started in 2004.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 20 is below the median of 80 across 3,492 interventional studies indexed under HIV Infections.
Median enrollment 60 across the 2,150 interventional studies, 135 across the 350 observational. Of the 2,530 that completed or were terminated, 558 (22%) have results posted.
This tab as a report to print or save as PDF → With an account.
857 of 2,802 have an industry lead sponsor. The 10 most frequent:
CytoDyn, Inc. is the lead sponsor of 24 studies on the registry; none are open to participants now.
Of its 12 completed or terminated interventional studies of FDA-regulated products, 12 (100%) have results posted.
CytoDyn, Inc. has 4 studies filed under HIV Infections — fewer than ten, so there is no comparison to draw.
51 of the studies in HIV Infections with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06550804Phase 3University of Illinois at ChicagoTesting a Real-time Electronic Antiretroviral Adherence Monitoring Intervention | 2027-03 |
| NCT04833829Emory UniversityCross-disciplinary HIV Integrated Mental Health Support Intervention | 2026-11 |
| NCT04577313University of ConnecticutHIV Treatment Adherence Dose Determination Trial | 2026-11-30 |
| NCT06679751Boston Medical CenterInfectious Disease (ID) Testing OUtreach in Carceral Hubs | 2026-12 |
| NCT06868641Columbia UniversityThe TAIL-PrEP Study | 2026-12 |
Add all 51 to your calendar (.ics) → With an account.
Among the 2,802 studies in HIV Infections with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of the study is to determine the safety and tolerability of PRO 140, an investigational anti-HIV drug, administered via intravenous infusion.
Study hypothesis: Single intravenous doses of PRO 140 can be safely administered to humans and will result in measurable concentrations of the product in serum.
PRO 140 is a man-made monoclonal antibody to the chemokine receptor CCR5, which serves as a co-receptor for HIV. In numerous preclinical models of HIV infection, PRO 140 broadly and potently blocks CCR5-mediated HIV entry without blocking the natural activity of CCR5. PRO 140 is being developed for therapy of HIV infected individuals. The purpose of this study is to evaluate the safety and tolerability of PRO 140 in HIV uninfected male volunteers. The pharmacokinetics and pharmacodynamics of PRO 140 will also be assessed in this study.
Participants in this study will be randomly assigned to receive a single dose of one of several possible doses of PRO 140 or placebo. Participants will remain in the clinic for observation and evaluation for 24 hours after the single-dose administration. Follow-up visits will occur at 2, 3, 5, 7, 10, 14, 28, 42, and 60 days post-treatment. Physical exams, electrocardiograms (ECGs), vital signs measurement, adverse event reporting, and blood and urine collection will occur at most visits.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Intravenous placebo for PRO 140
Drug: PRO 140
0.1 mg/kg PRO 140 by intravenous infusion
Drug: PRO 140
0.5 mg/kg PRO 140 by intravenous infusion
Drug: PRO 140
2.0 mg/kg PRO 140 by intravenous infusion
Drug: PRO 140
5.0 mg/kg PRO 140 by intravenous infusion
Drug: PRO 140
Monoclonal antibody to CCR5
Also known as: Humanized monoclonal antibody to CCR5
Safety and Tolerability of PRO 140
Time frame: 60 days
| Milestone | Placebo | PRO 140 Dose 1 | PRO 140 Dose 2 | PRO 140 Dose 3 | PRO 140 Dose 4 |
|---|---|---|---|---|---|
| Started | 4 | 4 | 4 | 4 | 4 |
| Completed | 4 | 4 | 4 | 4 | 4 |
| Not completed | 0 | 0 | 0 | 0 | 0 |
| number of subjects reporting AEs | Placebo | PRO 140 Dose 1 | PRO 140 Dose 2 | PRO 140 Dose 3 | PRO 140 Dose 4 |
|---|---|---|---|---|---|
| Safety and Tolerability of PRO 140 | 4 | 4 | 0 | 4 | 3 |
Collected over Adverse event data was collected over an 18-month period.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | — | 0/4 (0%) | 4/4 (100%) |
| PRO 140 Dose 1 | — | 1/4 (25%) | 4/4 (100%) |
| PRO 140 Dose 2 | — | 0/4 (0%) | 0/4 (0%) |
| PRO 140 Dose 3 | — | 0/4 (0%) | 4/4 (100%) |
| PRO 140 Dose 4 | — | 0/4 (0%) | 3/4 (75%) |
| Event | Placebo | PRO 140 Dose 1 | PRO 140 Dose 2 | PRO 140 Dose 3 | PRO 140 Dose 4 |
|---|---|---|---|---|---|
| Myocardial infarctionCardiac disorders | 0/4 | 1/4 | 0/4 | 0/4 | 0/4 |
| Event | Placebo | PRO 140 Dose 1 | PRO 140 Dose 2 | PRO 140 Dose 3 | PRO 140 Dose 4 |
|---|---|---|---|---|---|
| Pharyngolaryngeal painRespiratory, thoracic and mediastinal disorders | 0/4 | 0/4 | 0/4 | 3/4 | 1/4 |
| high creatine phosphokinase levelInvestigations | 2/4 | 0/4 | 0/4 | 0/4 | 2/4 |
| Aspartate aminotransferase increasedInvestigations | 2/4 | 0/4 | 0/4 | 0/4 | 0/4 |
| HeadacheNervous system disorders | 1/4 | 1/4 | 0/4 | 2/4 | 1/4 |
| Fatal Myocardial infarctionCardiac disorders | 0/4 | 1/4 | 0/4 | 0/4 | 0/4 |
| Abdominal pain upperGastrointestinal disorders | 0/4 | 0/4 | 0/4 | 1/4 | 0/4 |
| Loose stoolsGastrointestinal disorders | 0/4 | 0/4 | 0/4 | 1/4 | 0/4 |
| NauseaGastrointestinal disorders | 0/4 | 0/4 | 0/4 | 1/4 | 0/4 |
| Joint sprainInjury, poisoning and procedural complications | 0/4 | 1/4 | 0/4 | 0/4 | 0/4 |
| Alanine aminotransferase increasedInvestigations | 1/4 | 0/4 | 0/4 | 0/4 | 0/4 |
| Age, Categorical(Participants) | Placebo | PRO 140 Dose 1 | PRO 140 Dose 2 | PRO 140 Dose 3 | PRO 140 Dose 4 | Total |
|---|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 4 | 4 | 4 | 4 | 4 | 20 |
| >=65 years | 0 | 0 | 0 | 0 | 0 | 0 |
| Age, Continuous(years) | Placebo | PRO 140 Dose 1 | PRO 140 Dose 2 | PRO 140 Dose 3 | PRO 140 Dose 4 | Total |
|---|---|---|---|---|---|---|
| Mean | 26 ± 7 | 34 ± 13 | 30 ± 12 | 22 ± 2 | 21 ± 2 | 27 ± 9 |
| Sex: Female, Male(Participants) | Placebo | PRO 140 Dose 1 | PRO 140 Dose 2 | PRO 140 Dose 3 | PRO 140 Dose 4 | Total |
|---|---|---|---|---|---|---|
| Female | 0 | 0 | 0 | 0 | 0 | 0 |
| Male | 4 | 4 | 4 | 4 | 4 | 20 |
| Region of Enrollment(participants) | Placebo | PRO 140 Dose 1 | PRO 140 Dose 2 | PRO 140 Dose 3 | PRO 140 Dose 4 | Total |
|---|---|---|---|---|---|---|
| United States | 4 | 4 | 4 | 4 | 4 | 20 |
The record gives a start of Apr 2004, a primary completion of Nov 2005 and a completion of Mar 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Mar 2023, 17 years 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Leronlimab